IFTBF (Infant Bacterial Therapeutics AB) ROCE %: -97.51% (As of Mar. 2026)


IFTBF Infant Bacterial Therapeutics AB IFTBF
29 GF Score
Price $6.18
! 1 Warning Sign
View Full Analysis

What is Infant Bacterial Therapeutics AB ROCE %?

Infant Bacterial Therapeutics AB IFTBF 29 ROCE % is -97.51% as of Mar. 2026. GuruFocus rates IFTBF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Infant Bacterial Therapeutics AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -97.51%.

Infant Bacterial Therapeutics AB  (OTCPK:IFTBF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Infant Bacterial Therapeutics AB ROCE % Related Terms

Infant Bacterial Therapeutics AB ROCE % Historical Data

* Premium members only.

The historical data trend for Infant Bacterial Therapeutics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB ROCE % Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.20 -16.64 -38.88 -58.48 -55.33

Infant Bacterial Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.12 -54.97 -31.37 -67.18 -97.51
IFTBF
29GF Score
Infant Bacterial Therapeutics AB IFTBF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infant Bacterial Therapeutics AB ROCE % Calculation

Infant Bacterial Therapeutics AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-7.424/( ( (21.808 - 6.309) + (17.405 - 6.07) )/ 2 )
=-7.424/( (15.499+11.335)/ 2 )
=-7.424/13.417
=-55.33 %

Infant Bacterial Therapeutics AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-9.848/( ( (17.405 - 6.07) + (15.36 - 6.497) )/ 2 )
=-9.848/( ( 11.335 + 8.863 )/ 2 )
=-9.848/10.099
=-97.51 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -97.51% mean?
Infant Bacterial Therapeutics AB (IFTBF) has a ROCE % of -97.51% as of Mar. 2026.
Is Infant Bacterial Therapeutics AB's ROCE % too high?
Infant Bacterial Therapeutics AB's current ROCE % is -97.51%. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's ROCE % compare to VRTX and REGN?
Infant Bacterial Therapeutics AB's ROCE % of -97.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Infant Bacterial Therapeutics AB's current ROCE % is -97.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (IFTBF) has a current ROCE % of -97.51%. The current ROCE % is -97.51%. Infant Bacterial Therapeutics AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (IFTBF), the current ROCE % is -97.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infant Bacterial Therapeutics AB Business Description

Other Exchanges IBT B:Sweden9IB:Germany
Address Katarina Bangata 70, Stockholm, SWE, 116 42
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
29GF Score

Get the complete analysis for IFTBF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.18
Price